• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Detection of DNA sequence responsible for the interstitial lung disease specific for Japanese

Research Project

Project/Area Number 18H02820
Research Category

Grant-in-Aid for Scientific Research (B)

Allocation TypeSingle-year Grants
Section一般
Review Section Basic Section 53030:Respiratory medicine-related
Research InstitutionJichi Medical University

Principal Investigator

Hagiwara Koichi  自治医科大学, 医学部, 教授 (00240705)

Project Period (FY) 2018-04-01 – 2021-03-31
Project Status Completed (Fiscal Year 2020)
Budget Amount *help
¥17,030,000 (Direct Cost: ¥13,100,000、Indirect Cost: ¥3,930,000)
Fiscal Year 2020: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2019: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2018: ¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
Keywords薬剤性肺障害 / EGFR / EGFR-TKI / MUC4 / 日本人特異的 / EGFR阻害薬 / 肺障害 / 日本人 / 肺癌 / 疾患感受性遺伝子 / MUC4遺伝子 / チロシンキナーゼ
Outline of Final Research Achievements

The aim of the current study is to identify a genetic factor responsible for the interstitial lung disease specific for Japanese. Recently, vulnerability of Japanese to interstitial lung diseases has been widely recognized. First, drug-induced interstitial lung disease occurs at a higher frequency in Japanese than people in other ethnic groups. Second, acute exacerbation is more frequently observed in the patients with interstitial pulmonary fibrosis. These conditions often occur in medical services, and hinders safe medical services. We decided to elucidate the genetic factors that cause interstitial lung diseases in Japanese, and thus help to contribute to a safer medical services. We compared the non-synonymous SNPs in patients and healthy people and identified the MUC4 gene as a candidate gene.

Academic Significance and Societal Importance of the Research Achievements

日本人には肺障害が高率に発症する.2004年,肺がん治療薬ゲフィチニブが上市された直後から肺障害が多発した.ゲフィチニブによる肺障害は海外ではど報告されていない.特発性肺線維症急性増悪も,ゲフィチニブ肺障害同様,日本で高頻度に発生し,同じ病理像を示す.我々は,日本人特有の単一遺伝因子が薬剤性肺障害および特発性肺線維症の原因という作業仮説を設定し原因遺伝子を追求することとした.

Report

(4 results)
  • 2020 Annual Research Report   Final Research Report ( PDF )
  • 2019 Annual Research Report
  • 2018 Annual Research Report

URL: 

Published: 2018-04-23   Modified: 2022-01-27  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi